BR112016012435A2 - Vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 - Google Patents

Vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2

Info

Publication number
BR112016012435A2
BR112016012435A2 BR112016012435A BR112016012435A BR112016012435A2 BR 112016012435 A2 BR112016012435 A2 BR 112016012435A2 BR 112016012435 A BR112016012435 A BR 112016012435A BR 112016012435 A BR112016012435 A BR 112016012435A BR 112016012435 A2 BR112016012435 A2 BR 112016012435A2
Authority
BR
Brazil
Prior art keywords
vaccine
porcine circovirus
circovirus type
recombinantly expressed
orf2 protein
Prior art date
Application number
BR112016012435A
Other languages
English (en)
Other versions
BR112016012435A8 (pt
Inventor
Fachinger Vicky
Sno Melanie
Hendrik Witvliet Maarten
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49680926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016012435(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112016012435A2 publication Critical patent/BR112016012435A2/pt
Publication of BR112016012435A8 publication Critical patent/BR112016012435A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VACINA, E, USOS DE UMA PROTEÍNA ORF2 RECOMBINANTEMENTE EXPRESSADA DO CIRCOVÍRUS PORCINO TIPO 2. A presente invenção refere-se a uma vacina compreendendo um imunogênio não replicante do circovírus porcino tipo 2 para o uso no tratamento profilático de um animal que tem anticorpos circulantes direcionados contra o circovírus porcino tipo 2, contra uma infecção com circovírus porcino patogênico tipo 2 por uma administração de dose única da vacina na derme do animal.
BR112016012435A 2013-12-03 2014-12-02 vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 BR112016012435A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195515 2013-12-03
PCT/EP2014/076224 WO2015082458A1 (en) 2013-12-03 2014-12-02 Vaccine against porcine circo virus type 2

Publications (2)

Publication Number Publication Date
BR112016012435A2 true BR112016012435A2 (pt) 2017-08-08
BR112016012435A8 BR112016012435A8 (pt) 2018-01-30

Family

ID=49680926

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012435A BR112016012435A8 (pt) 2013-12-03 2014-12-02 vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2

Country Status (13)

Country Link
US (1) US10130698B2 (pt)
EP (1) EP3076996B1 (pt)
JP (1) JP6605469B2 (pt)
KR (1) KR20160093047A (pt)
CN (2) CN105848675A (pt)
BR (1) BR112016012435A8 (pt)
CA (1) CA2931137C (pt)
DK (1) DK3076996T3 (pt)
ES (1) ES2771899T3 (pt)
MX (1) MX369039B (pt)
PL (1) PL3076996T3 (pt)
RU (1) RU2712155C2 (pt)
WO (1) WO2015082458A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3076996T3 (en) 2013-12-03 2020-03-09 Intervet Int Bv Vaccine mod porcint circovirus type 2
DK3365001T3 (da) * 2015-10-22 2022-08-22 Intervet Int Bv Vaccine til at beskytte et mda-positivt dyr mod en lidelse, der udspringer af en infektion med lawsonia intracellularis
RU2746127C2 (ru) * 2016-03-23 2021-04-07 Интервет Интернэшнл Б.В. Вакцина для внутрикожного применения против инфекции вируса pcv2 и prrs
US11311614B2 (en) * 2017-04-13 2022-04-26 Intervet Inc. Vaccines containing swine pathogens for associated non-mixed use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236574A1 (en) 1995-11-30 1997-06-05 Daratech Pty. Ltd. Therapeutic and diagnostic compositions
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
RU2354399C2 (ru) 2003-07-24 2009-05-10 Мериал Лимитед Вакцинная композиция и способ индуцирования иммунологического ответа у животного
DK1709067T3 (da) 2004-01-22 2010-10-11 Intervet Int Bv Vacciner med underenhed af Lawsonia intracellularis
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ES2425228T3 (es) 2005-09-09 2013-10-14 Intervet International B.V. Vacuna contra el PCV-2
JP5739602B2 (ja) 2005-12-29 2015-06-24 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタの臨床症状の緩和のためのｐｃｖ２免疫原性組成物の使用
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
HUE033130T2 (en) 2006-12-15 2017-11-28 Boehringer Ingelheim Vetmedica Inc Treatment of seropositive pigs with anti-PCV2 antibody with PCV2 antigen
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
BRPI0907438A2 (pt) * 2008-01-23 2015-08-04 Boehringer Ingelheim Vetmed Composições imunogênicas para mycoplasma hyopneumoniae e pcv2 e métodos para produzir tais composições
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
DK3076996T3 (en) 2013-12-03 2020-03-09 Intervet Int Bv Vaccine mod porcint circovirus type 2
JP6488304B2 (ja) 2013-12-03 2019-03-20 インターベット インターナショナル ベー． フェー． ローソニア・イントラセルラリス（ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）及びブタサーコウイルス（ｐｏｒｃｉｎｅ ｃｉｒｃｏｖｉｒｕｓ）２に対するワクチン

Also Published As

Publication number Publication date
CA2931137A1 (en) 2015-06-11
RU2712155C2 (ru) 2020-01-24
MX2016007224A (es) 2016-07-21
DK3076996T3 (en) 2020-03-09
PL3076996T3 (pl) 2020-05-18
EP3076996A1 (en) 2016-10-12
BR112016012435A8 (pt) 2018-01-30
JP6605469B2 (ja) 2019-11-13
KR20160093047A (ko) 2016-08-05
EP3076996B1 (en) 2020-01-15
US20170157236A1 (en) 2017-06-08
MX369039B (es) 2019-10-25
CN110354258A (zh) 2019-10-22
ES2771899T3 (es) 2020-07-07
US10130698B2 (en) 2018-11-20
CA2931137C (en) 2023-03-14
WO2015082458A1 (en) 2015-06-11
JP2017501984A (ja) 2017-01-19
CN105848675A (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
UY36422A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CL2015002736A1 (es) Composición farmacéutica de clorhidrato de s-ketamina.
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
BR112015023507A2 (pt) vacina estável líquida, e, métodos para vacinar um bovino e para produzir uma vacina estável líquida
BR112016006048A8 (pt) composições antimicrobianas
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
PE20151588A1 (es) Vacuna contra el virus del dengue
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
AR098168A1 (es) Formulación estable de insulina glulisina
BR112015004515A2 (pt) composição imunogênica
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
CO2020000328A2 (es) Formulaciones a largo plazo
BR112016012435A2 (pt) Vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
PH12016500946A1 (en) Composition for preventing and curing mycoplasma infection
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
ES2616035T3 (es) Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.